Janknegt R, Nube M J, Van den Hoogenband H M, Oldenhof H G, Steenhoek A, Vree T B
Department of Clinical Pharmacy, Medisch Centrum Alkmaar, The Netherlands.
Pharm Weekbl Sci. 1988 Apr 22;10(2):86-9. doi: 10.1007/BF01962684.
The pharmacokinetics of methotrexate and its 7-hydroxy metabolite were studied in a patient undergoing continuous ambulatory peritoneal dialysis. A biphasic plasma-disappearance pattern of methotrexate was observed, with half-lives of 3.5 and 29 hours. The 7-hydroxy metabolite accumulated and showed a very slow rate of elimination, with an estimated final elimination half-life of over 120 hours. The mean peritoneal clearance rate of methotrexate was 0.13 l/h (range 0.05-0.20 l/h), dwell times significantly influenced the clearance rate. Strict monitoring of the methotrexate level, even after low doses, is necessary in continuous ambulatory peritoneal dialysis patients, to prevent serious bone marrow toxicity.
对一名接受持续性非卧床腹膜透析的患者的甲氨蝶呤及其7-羟基代谢物的药代动力学进行了研究。观察到甲氨蝶呤的血浆消除呈双相模式,半衰期分别为3.5小时和29小时。7-羟基代谢物蓄积,消除速率非常缓慢,估计最终消除半衰期超过120小时。甲氨蝶呤的平均腹膜清除率为0.13升/小时(范围0.05 - 0.20升/小时),驻留时间显著影响清除率。对于持续性非卧床腹膜透析患者,即使是低剂量后,也有必要严格监测甲氨蝶呤水平,以预防严重的骨髓毒性。